3bkd › Citations

Structural basis for the function and inhibition of an influenza virus proton channel.

Stouffer AL, Acharya R, Salom D, Levine AS, Di Costanzo L, Soto CS, Tereshko V, Nanda V, Stayrook S, DeGrado WF
Nature 451 596-9 (2008)
Cited: 380 times
EuropePMC logo PMID: 18235504

Abstract

The M2 protein from influenza A virus is a pH-activated proton channel that mediates acidification of the interior of viral particles entrapped in endosomes. M2 is the target of the anti-influenza drugs amantadine and rimantadine; recently, resistance to these drugs in humans, birds and pigs has reached more than 90% (ref. 1). Here we describe the crystal structure of the transmembrane-spanning region of the homotetrameric protein in the presence and absence of the channel-blocking drug amantadine. pH-dependent structural changes occur near a set of conserved His and Trp residues that are involved in proton gating. The drug-binding site is lined by residues that are mutated in amantadine-resistant viruses. Binding of amantadine physically occludes the pore, and might also perturb the pK(a) of the critical His residue. The structure provides a starting point for solving the problem of resistance to M2-channel blockers.

Reviews - 3bkd mentioned but not cited (13)

  1. Influences of membrane mimetic environments on membrane protein structures. Zhou HX, Cross TA. Annu Rev Biophys 42 361-392 (2013)
  2. Influence of solubilizing environments on membrane protein structures. Cross TA, Sharma M, Yi M, Zhou HX. Trends Biochem Sci 36 117-125 (2011)
  3. Influenza M2 proton channels. Pielak RM, Chou JJ. Biochim Biophys Acta 1808 522-529 (2011)
  4. M2e-Based Universal Influenza A Vaccines. Deng L, Cho KJ, Fiers W, Saelens X. Vaccines (Basel) 3 105-136 (2015)
  5. Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus. Wang J, Qiu JX, Soto C, DeGrado WF. Curr Opin Struct Biol 21 68-80 (2011)
  6. Helical membrane protein conformations and their environment. Cross TA, Murray DT, Watts A. Eur Biophys J 42 731-755 (2013)
  7. Modeling the membrane environment has implications for membrane protein structure and function: influenza A M2 protein. Zhou HX, Cross TA. Protein Sci 22 381-394 (2013)
  8. M2 protein from influenza A: from multiple structures to biophysical and functional insights. Cross TA, Dong H, Sharma M, Busath DD, Zhou HX. Curr Opin Virol 2 128-133 (2012)
  9. Mechanism of function of viral channel proteins and implications for drug development. Fischer WB, Wang YT, Schindler C, Chen CP. Int Rev Cell Mol Biol 294 259-321 (2012)
  10. Transmembrane communication: general principles and lessons from the structure and function of the M2 proton channel, K⁺ channels, and integrin receptors. Grigoryan G, Moore DT, DeGrado WF. Annu Rev Biochem 80 211-237 (2011)
  11. Microtubules in Influenza Virus Entry and Egress. Simpson C, Yamauchi Y. Viruses 12 E117 (2020)
  12. Transcendent Aspects of Proton Channels. DeCoursey TE. Annu Rev Physiol 86 357-377 (2024)
  13. Viral channel forming proteins--How to assemble and depolarize lipid membranes in silico. Fischer WB, Kalita MM, Heermann D. Biochim Biophys Acta 1858 1710-1721 (2016)

Articles - 3bkd mentioned but not cited (26)



Reviews citing this publication (87)

  1. Viroporins: structure and biological functions. Nieva JL, Madan V, Carrasco L. Nat Rev Microbiol 10 563-574 (2012)
  2. Drug resistance in influenza A virus: the epidemiology and management. Hussain M, Galvin HD, Haw TY, Nutsford AN, Husain M. Infect Drug Resist 10 121-134 (2017)
  3. Structural advances for the major facilitator superfamily (MFS) transporters. Yan N. Trends Biochem Sci 38 151-159 (2013)
  4. Structures of influenza A proteins and insights into antiviral drug targets. Das K, Aramini JM, Ma LC, Krug RM, Arnold E. Nat Struct Mol Biol 17 530-538 (2010)
  5. The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Wanka L, Iqbal K, Schreiner PR. Chem Rev 113 3516-3604 (2013)
  6. M2e-based universal influenza A vaccine. Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, Birkett A, Saelens X. Vaccine 27 6280-6283 (2009)
  7. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Schotsaert M, De Filette M, Fiers W, Saelens X. Expert Rev Vaccines 8 499-508 (2009)
  8. Entry of influenza A virus: host factors and antiviral targets. Edinger TO, Pohl MO, Stertz S. J Gen Virol 95 263-277 (2014)
  9. Protein-protein interactions in the membrane: sequence, structural, and biological motifs. Moore DT, Berger BW, DeGrado WF. Structure 16 991-1001 (2008)
  10. Membrane protein structure and dynamics from NMR spectroscopy. Hong M, Zhang Y, Hu F. Annu Rev Phys Chem 63 1-24 (2012)
  11. Viral proteins function as ion channels. Wang K, Xie S, Sun B. Biochim Biophys Acta 1808 510-515 (2011)
  12. The many faces of the adamantyl group in drug design. Liu J, Obando D, Liao V, Lifa T, Codd R. Eur J Med Chem 46 1949-1963 (2011)
  13. Structural basis for proton conduction and inhibition by the influenza M2 protein. Hong M, DeGrado WF. Protein Sci 21 1620-1633 (2012)
  14. Considering protonation as a posttranslational modification regulating protein structure and function. Schönichen A, Webb BA, Jacobson MP, Barber DL. Annu Rev Biophys 42 289-314 (2013)
  15. Membrane Protein Structure, Function, and Dynamics: a Perspective from Experiments and Theory. Cournia Z, Allen TW, Andricioaei I, Antonny B, Baum D, Brannigan G, Buchete NV, Deckman JT, Delemotte L, Del Val C, Friedman R, Gkeka P, Hege HC, Hénin J, Kasimova MA, Kolocouris A, Klein ML, Khalid S, Lemieux MJ, Lindow N, Roy M, Selent J, Tarek M, Tofoleanu F, Vanni S, Urban S, Wales DJ, Smith JC, Bondar AN. J Membr Biol 248 611-640 (2015)
  16. Perturbations of Native Membrane Protein Structure in Alkyl Phosphocholine Detergents: A Critical Assessment of NMR and Biophysical Studies. Chipot C, Dehez F, Schnell JR, Zitzmann N, Pebay-Peyroula E, Catoire LJ, Miroux B, Kunji ERS, Veglia G, Cross TA, Schanda P. Chem Rev 118 3559-3607 (2018)
  17. Structures of membrane proteins. Vinothkumar KR, Henderson R. Q Rev Biophys 43 65-158 (2010)
  18. Interaction and conformational dynamics of membrane-spanning protein helices. Langosch D, Arkin IT. Protein Sci 18 1343-1358 (2009)
  19. Viroporins: structure, function and potential as antiviral targets. Scott C, Griffin S. J Gen Virol 96 2000-2027 (2015)
  20. Viral escape from endosomes and host detection at a glance. Staring J, Raaben M, Brummelkamp TR. J Cell Sci 131 jcs216259 (2018)
  21. Viroporins and inflammasomes: A key to understand virus-induced inflammation. Farag NS, Breitinger U, Breitinger HG, El Azizi MA. Int J Biochem Cell Biol 122 105738 (2020)
  22. Voltage-gated proton channels find their dream job managing the respiratory burst in phagocytes. DeCoursey TE. Physiology (Bethesda) 25 27-40 (2010)
  23. Emerging antiviral strategies to interfere with influenza virus entry. Vanderlinden E, Naesens L. Med Res Rev 34 301-339 (2014)
  24. Anti-influenza agents from Traditional Chinese Medicine. Ge H, Wang YF, Xu J, Gu Q, Liu HB, Xiao PG, Zhou J, Liu Y, Yang Z, Su H. Nat Prod Rep 27 1758-1780 (2010)
  25. M2e-based universal influenza vaccines: a historical overview and new approaches to development. Mezhenskaya D, Isakova-Sivak I, Rudenko L. J Biomed Sci 26 76 (2019)
  26. Structure and Dynamics of Membrane Proteins from Solid-State NMR. Mandala VS, Williams JK, Hong M. Annu Rev Biophys 47 201-222 (2018)
  27. The molecular mystique of tetrodotoxin. Moczydlowski EG. Toxicon 63 165-183 (2013)
  28. Alpha-helical transmembrane peptides: a "divide and conquer" approach to membrane proteins. Bordag N, Keller S. Chem Phys Lipids 163 1-26 (2010)
  29. Virus-like particles as universal influenza vaccines. Kang SM, Kim MC, Compans RW. Expert Rev Vaccines 11 995-1007 (2012)
  30. The gates of ion channels and enzymes. Zhou HX, McCammon JA. Trends Biochem Sci 35 179-185 (2010)
  31. Emerging antiviral targets for influenza A virus. Krug RM, Aramini JM. Trends Pharmacol Sci 30 269-277 (2009)
  32. Molecular studies of influenza B virus in the reverse genetics era. Jackson D, Elderfield RA, Barclay WS. J Gen Virol 92 1-17 (2011)
  33. Influenza A Virus M2 Protein: Roles from Ingress to Egress. Manzoor R, Igarashi M, Takada A. Int J Mol Sci 18 E2649 (2017)
  34. Self-assembly and function of primitive cell membranes. Pohorille A, Deamer D. Res Microbiol 160 449-456 (2009)
  35. Cholesterol-binding viral proteins in virus entry and morphogenesis. Schroeder C. Subcell Biochem 51 77-108 (2010)
  36. Development of effective anti-influenza drugs: congeners and conjugates - a review. Shie JJ, Fang JM. J Biomed Sci 26 84 (2019)
  37. Voltage-gated proton channels. DeCoursey TE. Cell Mol Life Sci 65 2554-2573 (2008)
  38. Recent progress in structure-based anti-influenza drug design. Du J, Cross TA, Zhou HX. Drug Discov Today 17 1111-1120 (2012)
  39. Flu channel drug resistance: a tale of two sites. Pielak RM, Chou JJ. Protein Cell 1 246-258 (2010)
  40. Voltage-gated proton channels: what's next? DeCoursey TE. J Physiol 586 5305-5324 (2008)
  41. Progress of small molecular inhibitors in the development of anti-influenza virus agents. Wu X, Wu X, Sun Q, Zhang C, Yang S, Li L, Jia Z. Theranostics 7 826-845 (2017)
  42. Virus entry paradigms. Kalia M, Jameel S. Amino Acids 41 1147-1157 (2011)
  43. Viruses and endosome membrane dynamics. Gruenberg J. Curr Opin Cell Biol 21 582-588 (2009)
  44. Disentangling the Frames, the State of Research on the Alphavirus 6K and TF Proteins. Ramsey J, Mukhopadhyay S. Viruses 9 E228 (2017)
  45. New technologies for influenza vaccines. Dormitzer PR, Tsai TF, Del Giudice G. Hum Vaccin Immunother 8 45-58 (2012)
  46. Next-generation direct-acting influenza therapeutics. Toots M, Plemper RK. Transl Res 220 33-42 (2020)
  47. Water in Nanopores and Biological Channels: A Molecular Simulation Perspective. Lynch CI, Rao S, Sansom MSP. Chem Rev 120 10298-10335 (2020)
  48. Epitope-based approaches to a universal influenza vaccine. Gottlieb T, Ben-Yedidia T. J Autoimmun 54 15-20 (2014)
  49. Put a cork in it: Plugging the M2 viral ion channel to sink influenza. Jalily PH, Duncan MC, Fedida D, Wang J, Tietjen I. Antiviral Res 178 104780 (2020)
  50. Functions of Coronavirus Accessory Proteins: Overview of the State of the Art. Fang P, Fang L, Zhang H, Xia S, Xiao S. Viruses 13 1139 (2021)
  51. The minimalist architectures of viroporins and their therapeutic implications. OuYang B, Chou JJ. Biochim Biophys Acta 1838 1058-1067 (2014)
  52. New-generation screening assays for the detection of anti-influenza compounds targeting viral and host functions. Beyleveld G, White KM, Ayllon J, Shaw ML. Antiviral Res 100 120-132 (2013)
  53. Viral channel forming proteins - modeling the target. Fischer WB, Hsu HJ. Biochim Biophys Acta 1808 561-571 (2011)
  54. Viroporins: Structure, function, and their role in the life cycle of SARS-CoV-2. Breitinger U, Farag NS, Sticht H, Breitinger HG. Int J Biochem Cell Biol 145 106185 (2022)
  55. Novel vaccines against influenza viruses. Kang SM, Song JM, Compans RW. Virus Res 162 31-38 (2011)
  56. Golgi anti-apoptotic protein: a tale of camels, calcium, channels and cancer. Carrara G, Parsons M, Saraiva N, Smith GL. Open Biol 7 170045 (2017)
  57. Viral channel-forming proteins. Fischer WB, Krüger J. Int Rev Cell Mol Biol 275 35-63 (2009)
  58. Viroporins in the Influenza Virus. To J, Torres J. Cells 8 E654 (2019)
  59. Antiviral Approaches against Influenza Virus. Kumari R, Sharma SD, Kumar A, Ende Z, Mishina M, Wang Y, Falls Z, Samudrala R, Pohl J, Knight PR, Sambhara S. Clin Microbiol Rev 36 e0004022 (2023)
  60. Structural and energetic analysis of drug inhibition of the influenza A M2 proton channel. Gu RX, Liu LA, Wei DQ. Trends Pharmacol Sci 34 571-580 (2013)
  61. NMR structures of membrane proteins in phospholipid bilayers. Radoicic J, Lu GJ, Opella SJ. Q Rev Biophys 47 249-283 (2014)
  62. Solid-State NMR for Studying the Structure and Dynamics of Viral Assemblies. Lecoq L, Fogeron ML, Meier BH, Nassal M, Böckmann A. Viruses 12 E1069 (2020)
  63. Targeting the Channel Activity of Viroporins. To J, Surya W, Torres J. Adv Protein Chem Struct Biol 104 307-355 (2016)
  64. Why do proteins aggregate? "Intrinsically insoluble proteins" and "dark mediators" revealed by studies on "insoluble proteins" solubilized in pure water. Song J. F1000Res 2 94 (2013)
  65. From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs? Cheng CK, Tsai CH, Shie JJ, Fang JM. Future Med Chem 6 757-774 (2014)
  66. Influenza Viruses: Harnessing the Crucial Role of the M2 Ion-Channel and Neuraminidase toward Inhibitor Design. Mtambo SE, Amoako DG, Somboro AM, Agoni C, Lawal MM, Gumede NS, Khan RB, Kumalo HM. Molecules 26 880 (2021)
  67. Resistance characteristics of influenza to amino-adamantyls. Astrahan P, Arkin IT. Biochim Biophys Acta 1808 547-553 (2011)
  68. The present and future of solution NMR in investigating the structure and dynamics of channels and transporters. Oxenoid K, Chou JJ. Curr Opin Struct Biol 23 547-554 (2013)
  69. Drug sensitivity, drug-resistant mutations, and structures of three conductance domains of viral porins. Sharma M, Li C, Busath DD, Zhou HX, Cross TA. Biochim Biophys Acta 1808 538-546 (2011)
  70. Mimicking biopolymers on a molecular scale: nano(bio)technology based on engineered proteins. Grunwald I, Rischka K, Kast SM, Scheibel T, Bargel H. Philos Trans A Math Phys Eng Sci 367 1727-1747 (2009)
  71. Antiviral Potential of Natural Resources against Influenza Virus Infections. Eichberg J, Maiworm E, Oberpaul M, Czudai-Matwich V, Lüddecke T, Vilcinskas A, Hardes K. Viruses 14 2452 (2022)
  72. NMR structures of polytopic integral membrane proteins. Patching SG. Mol Membr Biol 28 370-397 (2011)
  73. The Structure, Function, and Pathobiology of the Influenza A and B Virus Ion Channels. Lamb RA. Cold Spring Harb Perspect Med 10 a038505 (2020)
  74. A functional NMR for membrane proteins: dynamics, ligand binding, and allosteric modulation. Oxenoid K, Chou JJ. Protein Sci 25 959-973 (2016)
  75. Virus Structures and Dynamics by Magic-Angle Spinning NMR. Porat-Dahlerbruch G, Goldbourt A, Polenova T. Annu Rev Virol 8 219-237 (2021)
  76. Asymmetric perturbations of signalling oligomers. Maksay G, Tőke O. Prog Biophys Mol Biol 114 153-169 (2014)
  77. Current landscape and future prospects of antiviral drugs derived from microbial products. Takizawa N, Yamasaki M. J Antibiot (Tokyo) (2017)
  78. Solid-state NMR structures of integral membrane proteins. Patching SG. Mol Membr Biol 32 156-178 (2015)
  79. Recent advances in pharmacophore modeling and its application to anti-influenza drug discovery. Shin WJ, Seong BL. Expert Opin Drug Discov 8 411-426 (2013)
  80. Gaining insight into membrane protein structure using isotope-edited FTIR. Manor J, Arkin IT. Biochim Biophys Acta 1828 2256-2264 (2013)
  81. Alchemical Free Energy Calculations on Membrane-Associated Proteins. Papadourakis M, Sinenka H, Matricon P, Hénin J, Brannigan G, Pérez-Benito L, Pande V, van Vlijmen H, de Graaf C, Deflorian F, Tresadern G, Cecchini M, Cournia Z. J Chem Theory Comput 19 7437-7458 (2023)
  82. Modulating Neurological Complications of Emerging Infectious Diseases: Mechanistic Approaches to Candidate Phytochemicals. Fakhri S, Mohammadi Pour P, Piri S, Farzaei MH, Echeverría J. Front Pharmacol 12 742146 (2021)
  83. Recent Advances in Application of Computer-Aided Drug Design in Anti-Influenza A Virus Drug Discovery. Yu D, Wang L, Wang Y. Int J Mol Sci 23 4738 (2022)
  84. From Acid Activation Mechanisms of Proton Conduction to Design of Inhibitors of the M2 Proton Channel of Influenza A Virus. Aledavood E, Selmi B, Estarellas C, Masetti M, Luque FJ. Front Mol Biosci 8 796229 (2021)
  85. Inhibitors of influenza viruses replication: a patent evaluation (WO2013019828). Xie Y, Song W, Xiao W, Gu C, Xu W. Expert Opin Ther Pat 23 1517-1524 (2013)
  86. [Function of influenza virus RNA polymerase based on structure]. Naito T, Kawaguchi A, Nagata K. Uirusu 59 1-11 (2009)
  87. [Stoichiometric analysis of oligomerization of membrane proteins using coiled-coil labeling and in-cell spectroscopy]. Kawano K. Yakugaku Zasshi 134 931-937 (2014)

Articles citing this publication (254)



Quick links